In its COVID-19 announcement, Ximedica has confirmed that its manufacturing facility remains open under the “essential service” classification and that is focusing on US national efforts to help address the challenges surrounding ventilator and PPE supplies. It also highlighted its core strength in engineering, with more than 200 engineers who have established several highly effective means of remote collaboration.
We wanted to reach out to let you know that the health and well-being of our clients, vendors, employees and communities are top concerns for Ximedica, and we are closely monitoring the COVID-19 health situation that is currently impacting our global community. We are committed to limiting the spread of this virus and safeguarding the health of the greater community.
We also wanted you to know that Ximedica has a core strength in engineering, with more than 200 engineers who have extensive engineering capabilities across a wide range of specialities (e.g. mechanical, electrical, systems, software, bio-chemical and fluidics engineering). In addition, Ximedica has established several highly effective means of remote collaboration using techniques that we have developed and honed over 30 years in this space. This has enabled the product design and development process to proceed in a cost-effective manner and within a best in class Quality Management System.
Our manufacturing facility remains open under the “essential service” classification as we focus on augmenting national efforts to help address the challenges surrounding ventilator and PPE supplies. We have over 70,000 sq. ft. of manufacturing space which is ISO13485 certified and an FDA registered device manufacturer, that also includes Class III PMA and implantable products. We offer Class 7 and Class 8 cleanroom environments, production line and assembly capabilities, 3D printing, CNC machining and rapid prototyping for tools and moulds.
The pandemic has exposed fundamental gaps that will bring a number of healthcare trends into the spotlight going forward. In a series of white papers and interviews, we look at the future of healthcare innovation post COVID-19. We take a broad view of the gaps COVID-19 exposed, accelerated emerging trends, and a new way of looking at healthcare innovation that places the healthcare system at the centre. Download the the first in whitepaper in these series and check our website for additional publications.
During this unusual and challenging situation, we wanted to remind you that Ximedica is well positioned to continue to help you pursue your goals and objectives as the result of our model—as we always have. If you are experiencing challenges or impacts to your current programs, please do not hesitate to reach out to us to discuss the potential for collaboration and assistance.
Link to Press Release